ArriVent BioPharma, Inc.

ArriVent BioPharma, Inc.

AVBPNYSE / NASDAQHealthcareSmall cap

$10.52-$0.74 (-6.6%)

Last close · Data as of Nov 20, 2026

Market cap
$1.5B
Revenue
$0.00
ROCE
-57.8%

-47.6% over the last year

ArriVent BioPharma, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-44.2%
3M
-63.9%
6M
-61.4%
1Y
-47.6%
5Y
Short history
  • A period is left blank when the price history is shorter than the period.

52-week range

Day change -$0.74 (-6.6%) from $11 to $11 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in AVBP, bought on each weekday since 2024.

News & filings

What ArriVent BioPharma filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 166 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are more than ten times current liabilities.
  • Revenue is too small for margins and growth rates to be read, so those points are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers.

Read moreShow less

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Sector
Healthcare
Shares outstanding
42.5M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.5B
P/B
5.0x
52-week high
$34.74
52-week low
$10.52

Profitability

ROE
-54.1%
ROCE
-57.8%
ROIC
-53.6%
ROA
-49.9%

Growth

Revenue
$0.00
Net profit growth, 1Y
106.6%
Free cash flow
-$160.6M

Solvency

Current ratio
12.83
Debt / Equity
0.00
Debt / Assets
0.00
CFO / Net profit
0.97
Cash / Market cap
20.3%

Revenue and net profit

Annual revenue, with net profit as the dashed line.

ArriVent BioPharma, Inc. revenue and net profit by fiscal year
ArriVent BioPharma, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$36.9M
FY2023$0.00-$69.3M
FY2024$0.00-$80.5M
FY2025$0.00-$166.3M

Cash flows

FY2025: -$160.6M from operations, -$160.6M free after investment (dashed).

ArriVent BioPharma, Inc. operating and free cash flow by fiscal year
ArriVent BioPharma, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$43.6M-$43.6M
FY2023-$55.8M-$55.8M
FY2024-$70.2M-$70.2M
FY2025-$160.6M-$160.6M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$0.00
EBITDA
-$177.5M
Net profit
-$166.3M
Cash from operations
-$160.6M
Free cash flow
-$160.6M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$0.00-$177.5M-$166.3M-$160.6M-54.1%—+106.6%

Monthly returns

Month-by-month returns of AVBP across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$333.2M
Liabilities$25.9M
Equity$307.2M
Paid-in capital$711.9M
Retained earnings-$404.6M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; AVBP highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

No company in this group has a positive P/E.

Not shown (no positive earnings and no EV / Sales): ArriVent BioPharma, Inc., Amylyx Pharmaceuticals, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
ArriVent BioPharma, Inc.AVBPthis company$1.5B—5.0x-54.1%—
Amylyx Pharmaceuticals, Inc.AMLX$1.6B-11.0x5.2x-47.4%-9.0x
agilon health, inc.AGL$1.6B—12.5x-308.8%—
Nurix Therapeutics, Inc.NRIX$1.6B—2.9x-49.1%—
Sonida Senior Living, Inc.SNDA$1.6B-22.2x-142770.5x643445.5%96.8x
Vir Biotechnology, Inc.VIR$1.5B—2.0x-57.2%—
PROCEPT BioRobotics CorporationPRCT$1.5B-16.1x4.2x-26.1%-15.6x
AnaptysBio, Inc.ANAB$1.5B—40.4x-35.6%17.4x
STAAR Surgical CompanySTAA$1.5B-18.5x4.3x-23.4%-36.9x
Peer median—-17.3x4.3x-41.5%-9.0x

Year-to-date ROI

AVBP since 1 January, against earlier years.

Historical volatility

AVBP's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

LineFY2025
Operating expensesOperating Expense$177.5M
Research and developmentResearch And Development$153.3M
Total expensesTotal Expenses$177.5M
Pretax incomePretax Income-$166.3M

Learn while you research

Academy chapters picked for ArriVent BioPharma, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →